Pharmacological properties

Pharmacodynamics. tsitikolin stimulates biosynthesis of structural phospholipids of membranes of neurons. tsitikolin improves functioning of such membrane mechanisms as ionic pumps and neuroceptors without which regulation normal carrying out nervous impulses is impossible. thanks to the stabilizing action on a membrane of neurons tsitikolin shows antiedematous effects which promote a brain hypostasis reabsorption.

Tsitikolin inhibits activation of some phospholipases (A1, A2, C and D), reducing education of free radicals, prevents destruction of membrane systems and keeps antioxidant protective systems, such as glutathione.

Tsitikolin keeps a neural stock of energy, inhibits apoptosis and stimulates synthesis of acetylcholine.

Tsitikolin also has preventive neurotyre-tread effect in focal ischemia of a brain.

Tsitikolin authentically raises indicators of functional recovery at patients with an acute disorder of cerebral circulation that matches delay of growth of an ischemic brain damage according to neuroimaging.

At patients with a craniocereberal injury tsitikolin is accelerated by restoration and reduces duration and intensity of a posttraumatic syndrome.

Tsitikolin improves the level of attention and consciousness, promotes reduction of severity of amnesia, the cognitive and neurologic disorders connected with brain ischemia.

Pharmacokinetics. After administration of medicament the substantial increase of level of sincaline in blood plasma is observed. Drug is metabolized in intestines and a liver with formation of sincaline and cytidine.

After introduction tsitikolin it is widely distributed in structures of a brain with fast inclusion of fraction of sincaline in structural phospholipids and fractions of cytidine in cytidine nucleotides and nucleic acids. In a brain tsitikolin it is built in cellular, cytoplasmic and mitochondrial membranes, being integrated into structure of phospholipid fraction.

in urine and Calais (3%). About 12% are removed through FROM ₂ expired air. During removal of medicament with urine allocate two phases: the first phase during 36 h in which clearance rate decreases quickly and the second phase in which clearance rate decreases much more slowly. The same staging is observed at removal through airways. Clearance rate FROM ₂ decreases quickly, approximately during 15 h, then decreases much more slowly.

Indication

Stroke, sharp phase of disturbances of cerebral circulation and also complication and consequence of disturbances of cerebral circulation. craniocereberal injury and its neurologic consequences. cognitive disturbances and behavior disorders owing to chronic vascular and degenerative cerebral disorders.

Use

Recomendovanaya a dose for adult 500–2000 mg/days depending on weight of symptoms.

to use Drug in/in or in oil.

In/in medicament it can be appointed in the form of a slow injection (within 3–5 min., depending on a dose) or in/in by drop infusion (40–60 drops a minute).

Maximum daily dose — 2000 mg.

Period of treatment depends on weight of a course of the disease and is determined by the doctor individually. to Patients of advanced age of dose adjustment it is not required by

to p.

for single use. The medicament needs to be administered at once after opening of an ampoule. Unused solution should be destroyed.

to all in/in isotonic solutions and also to hypertensive solutions of glucose.

If necessary treatment is continued by medicament in the form of solution for intake.

Contraindication

Hypersensitivity to medicament components. the raised tone of parasympathetic nervous system.

Side effects

Nervous system: profound headache, vertigo, hallucinations.

Cardiovascular system: AG, arterial hypotension, tachycardia.

Respiratory system: asthma.

Digestive tract: nausea, vomiting, diarrhea.

Immune system: allergic reactions, including rashes, hyperaemia, dieback, urticaria, purpura, itching, Quincke's disease, acute anaphylaxis.

General reactions: fever, changes in the injection site.

Special instructions

In a case in/in uses needs to administer the medicament slowly (for 3–5 min. depending on the entered dose).

in case of use in/in by drop infusion speed of injection has to make 40–60 drops a minute.

At steady intracraneal hemorrhage should not exceed a dose of 1000 mg/days and speed in/in injections (30 drops a minute).

Use during pregnancy and feeding by a breast. There are no sufficient data on use of a tsitikolin for pregnant women. Data on penetration of a tsitikolin into breast milk and its action on a fruit are unknown. During pregnancy or feeding it is only when the expected for mother exceeds risk for a fruit or the child necessary to appoint medicine a breast.

Children. Experience of use of medicament for children is limited.

Ability to influence speed of response at control of vehicles or other mechanisms. In individual cases some side reactions from central nervous system can affect ability to run vehicles and to work with difficult mechanisms.

Interaction

should not use medicament along with the medicaments containing Meclofenoxatum.

is Strengthened by effect of a levodopa.

Incompatibility. Not to apply the solvents which are not specified in the section USE.

Overdose

About cases of overdose it was not reported.

Storage conditions

In original packing at a temperature not above 25 °C.